FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 906 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR 2022 ASCO Annual Meeting Research Round Up: New Research in Head... August 25, 2022 NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... December 13, 2019 EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib December 18, 2020 Women in Science: Celebrating with our Women of Influence initiative March 15, 2023 Load more HOT NEWS Ending smoking could free up 75,000 GP appointments each month Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Why Cancer Survivors Should Have a Written Survivorship Care Plan AI and remote monitoring are shaping a new patient journey in...
